SCHEMBL18264154

SCHEMBL18264154

Nc1n[nH]c2c1c(Nc1ccc(C(=O)O)cc1)nc1ccccc12

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.53
ABCC1 P33527 1/20 0.53
MEN1 O00255 5/20 0.52
KMT2A Q03164 5/20 0.52
SIRT5 Q9NXA8 1/20 0.52
ATM Q13315 1/20 0.51
ABCB1 P08183 1/20 0.49
PIN1 Q13526 2/20 0.47
EGFR P00533 2/20 0.47
KDR P35968 1/20 0.47
CSNK2A1 P68400 1/20 0.47
RORC P51449 1/20 0.46
MAPK14 Q16539 1/20 0.46
POLB P06746 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
TNKS O95271 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MERTK Q12866 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18264176 0.91 MAPT (0.49) ABCG2ABCC1MEN1KMT2ASIRT5
SCHEMBL18264175 0.88 KDM1A (0.52) ABCG2MEN1KMT2AEGFRKDR
SCHEMBL18264402 0.88 EGFR (0.47) ABCG2MEN1KMT2AEGFRKDR
SCHEMBL18264174 0.87 GAA (0.52) ABCG2MEN1KMT2APOLB
SCHEMBL18264156 0.84 NPY5R (0.50) ABCG2MEN1KMT2APOLBNPC1
SCHEMBL18264161 0.84 ABCG2 (0.51) ABCG2MEN1KMT2AEGFRKDR
SCHEMBL18264159 0.84 MAPT (0.52) ABCG2MEN1KMT2AEGFRKDR
SCHEMBL18264171 0.82 KMT2A (0.54) ABCG2ABCC1MEN1KMT2AABCB1
SCHEMBL18264152 0.81 MEN1 (0.56) ABCG2MEN1KMT2AABCB1POLB
SCHEMBL18264164 0.81 ABCG2 (0.52) ABCG2MEN1KMT2AEGFRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP claimed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US claimed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP claimed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO claimed
EP-3662751-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2021-10-13 EP disclosed
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-10-05 US disclosed
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-07-06 US disclosed
EP-3662751-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE Kaohsiung Medical University (TW) 2020-06-10 EP disclosed
US-20200113878-A1 PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2020-04-16 US disclosed
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP disclosed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US disclosed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP disclosed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE UGT1A3, UGT1A1, GUSB ABCG2 1289/4885ABCC1 234/4885MEN1 4572/4885
US-20200113878-A1 PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase UGT1A3, UGT1A1, GUSB ABCG2 1289/4885ABCC1 234/4885MEN1 4572/4885
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 ABCG2 1243/4885ABCC1 231/4885MEN1 4607/4885
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 ABCG2 1243/4885ABCC1 231/4885MEN1 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.